Thread
:
Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation
View Single Post
01-16-2013, 11:21 PM
#
1
News
Senior Member
Join Date: Oct 2007
Posts: 18,983
Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
More...
News
View Public Profile
Send a private message to News
Find More Posts by News